The company disclosed preliminary results in mid January, but it left out important metrics such as earnings per share for the fourth quarter.

Lipoprotein(a) has long been recognized as a critical marker for people at risk of cardiovascular disease. However, the health care industry has lacked the tools to tackle the problem.

The Washington University trial comes as part of a larger platform study which hopes to understand if Alzheimer's disease can ...

Developers celebrate gains for advances with radiopharmaceuticals while regulators and isotope suppliers work to keep up.

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

The fourth-quarter earnings season for the drug and biotech sector will be in full swing this week with many large drugmakers ...

UnitedHealth Group, AbbVie, and Eli Lilly and Company are the three Medical stocks to watch today, according to MarketBeat’s stock screener tool. Medical stocks refer to equities in companies that are ...

The colon cancer BRAFF mutation study is one of the first to be initiated under the FDA’s Project FrontRunner.

A holistic or integrative approach to hair loss considers the hair growth cycle and hair loss from a nutritional, ...

In the wake of the U.S. Food and Drug Administration’s approval of Zepbound to treat moderate to severe obstructive sleep ...